327 related articles for article (PubMed ID: 30917059)
1. Neurophysiology of the brain stem in Parkinson's disease.
Bove C; Travagli RA
J Neurophysiol; 2019 May; 121(5):1856-1864. PubMed ID: 30917059
[TBL] [Abstract][Full Text] [Related]
2. The substantia nigra modulates proximal colon tone and motility in a vagally-dependent manner in the rat.
Xing T; Nanni G; Burkholder CR; Browning KN; Travagli RA
J Physiol; 2023 Nov; 601(21):4751-4766. PubMed ID: 37772988
[TBL] [Abstract][Full Text] [Related]
3. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
4. What is the Evidence That Parkinson's Disease is a Prion Disorder, Which Originates in the Gut?
Kujawska M; Jodynis-Liebert J
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30424585
[TBL] [Abstract][Full Text] [Related]
5. A Nigro-Vagal Pathway Controls Gastric Motility and Is Affected in a Rat Model of Parkinsonism.
Anselmi L; Toti L; Bove C; Hampton J; Travagli RA
Gastroenterology; 2017 Dec; 153(6):1581-1593. PubMed ID: 28912019
[TBL] [Abstract][Full Text] [Related]
6. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
[TBL] [Abstract][Full Text] [Related]
7. Altered Expression of D1 and D2 Dopamine Receptors in Vagal Neurons Innervating the Gastric Muscularis Externa in a Parkinson's Disease Rat Model.
Wang ZY; Lian H; Zhou L; Zhang YM; Cai QQ; Zheng LF; Zhu JX
J Parkinsons Dis; 2016 May; 6(2):317-23. PubMed ID: 27164043
[TBL] [Abstract][Full Text] [Related]
8. Pathological correlates of gastrointestinal dysfunction in Parkinson's disease.
Cersosimo MG; Benarroch EE
Neurobiol Dis; 2012 Jun; 46(3):559-64. PubMed ID: 22048068
[TBL] [Abstract][Full Text] [Related]
9. Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra.
Howells DW; Porritt MJ; Wong JY; Batchelor PE; Kalnins R; Hughes AJ; Donnan GA
Exp Neurol; 2000 Nov; 166(1):127-35. PubMed ID: 11031089
[TBL] [Abstract][Full Text] [Related]
10. Altered gut microbiota and intestinal permeability in Parkinson's disease: Pathological highlight to management.
Sharma S; Awasthi A; Singh S
Neurosci Lett; 2019 Nov; 712():134516. PubMed ID: 31560998
[TBL] [Abstract][Full Text] [Related]
11. Parkinson's disease and alpha-synucleinopathies: from arising pathways to therapeutic challenge.
Miraglia F; Betti L; Palego L; Giannaccini G
Cent Nerv Syst Agents Med Chem; 2015; 15(2):109-16. PubMed ID: 25896035
[TBL] [Abstract][Full Text] [Related]
12. Intragastric proteasome inhibition induces alpha-synuclein-immunopositive aggregations in neurons in the dorsal motor nucleus of the vagus in rats.
Miwa H; Kubo T; Suzuki A; Kondo T
Neurosci Lett; 2006 Jun; 401(1-2):146-9. PubMed ID: 16600504
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein transgenic mice display age-related slowing of gastrointestinal motility associated with transgene expression in the vagal system.
Noorian AR; Rha J; Annerino DM; Bernhard D; Taylor GM; Greene JG
Neurobiol Dis; 2012 Oct; 48(1):9-19. PubMed ID: 22722052
[TBL] [Abstract][Full Text] [Related]
14. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease.
Damier P; Hirsch EC; Agid Y; Graybiel AM
Brain; 1999 Aug; 122 ( Pt 8)():1437-48. PubMed ID: 10430830
[TBL] [Abstract][Full Text] [Related]
15. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
16. Causes and consequences of degeneration of the dorsal motor nucleus of the vagus nerve in Parkinson's disease.
Greene JG
Antioxid Redox Signal; 2014 Aug; 21(4):649-67. PubMed ID: 24597973
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of calcium-sensing receptor by its antagonist promotes gastrointestinal motility in a Parkinson's disease mouse model.
Li YH; Jiang ZX; Xu Q; Jin TT; Huang JF; Luan X; Li C; Chen XY; Wong KH; Dong XL; Sun XR
Biomed Pharmacother; 2024 May; 174():116518. PubMed ID: 38565057
[TBL] [Abstract][Full Text] [Related]
18. Gastric motor dysfunctions in Parkinson's disease: Current pre-clinical evidence.
Pellegrini C; Antonioli L; Colucci R; Ballabeni V; Barocelli E; Bernardini N; Blandizzi C; Fornai M
Parkinsonism Relat Disord; 2015 Dec; 21(12):1407-14. PubMed ID: 26499757
[TBL] [Abstract][Full Text] [Related]
19. Motor and non-motor features of Parkinson's disease - a review of clinical and experimental studies.
Lima MM; Martins EF; Delattre AM; Proenca MB; Mori MA; Carabelli B; Ferraz AC
CNS Neurol Disord Drug Targets; 2012 Jun; 11(4):439-49. PubMed ID: 22483309
[TBL] [Abstract][Full Text] [Related]
20. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
